New Developments in Prostate Cancer Treatment
A prostate cancer diagnosis does not mean every patient needs the same immediate treatment. Some tumours grow slowly, while others require closer assessment or more intensive care. Current advances help us plan around the stage, aggressiveness and molecular features of the disease. Input from urology, medical oncology, radiation oncology and, when appropriate, nuclear medicine helps bring these findings together. [1] For low-risk cancer confined to the prostate, active surveillance can be appropriate. Regular PSA testing, clinical assessment, MRI and biopsies when needed allow treatment to begin if the disease changes. When surgery or radiotherapy is required, cancer control is considered alongside urinary and sexual function. PACE-B showed that five-session stereotactic radiotherapy can be an effective alternative to longer schedules for selected patients with low- or intermediate-risk disease. [1,2] In metastatic hormone-sensitive disease, adding a newer hormonal medicine to testosterone-suppressing treatment has become an important approach for suitable patients. Docetaxel may also be included for some. The 2025 US approval of darolutamide with basic androgen deprivation, without requiring docetaxel, expanded these options. The extent of disease and the patient’s general health help guide the choice. [1,3] Genetic testing is also guiding treatment earlier. Changes in BRCA1/2 and other DNA repair genes help identify patients who may benefit from PARP inhibitors. In 2026, talazoparib with enzalutamide received US approval for metastatic hormone-sensitive disease with specified DNA repair gene changes. Basic testosterone suppression continues alongside the combination. Finding a relevant genetic change does not mean every patient will benefit to the same degree. [4] Another 2026 development was US approval of capivasertib with abiraterone and prednisone for PTEN-deficient metastatic hormone-sensitive disease. Alongside androgen deprivation, this approach targets a cell-growth signalling pathway. PTEN deficiency must be assessed with an appropriate test, and monitoring includes high blood sugar, diarrhoea and skin reactions. This is an option for a defined group rather than everyone with metastatic cancer. [5] PSMA-targeted radioligand therapy is moving into earlier treatment settings too. Lutetium-177 is attached to a molecule that delivers radiation to PSMA-expressing cancer cells. In 2026, lutetium-177 vipivotide tetraxetan received US approval with a newer hormonal medicine for PSMA-positive metastatic hormone-sensitive disease, with eligibility assessed by an appropriate PSMA PET scan. Basic androgen deprivation continues. Kidney function and blood counts are assessed before treatment and monitored during care. [6] These options are most valuable when matched to the individual patient. Bone health, physical activity, cardiovascular and metabolic health, and quality of life deserve attention throughout treatment. Expected benefits, side effects and availability in Türkiye should be discussed openly with patients and their families. Sources [1] NCI · Prostate cancer | [2] PACE-B · NEJM | [3] ARANOTE · FDA | [4] TALAPRO-3 · FDA 2026 | [5] CAPItello-281 · FDA 2026 | [6] PSMAddition · FDA 2026
In prostate-confined, low-risk disease, active surveillance can be a suitable option. This approach aims to monitor the disease with regular PSA tests, examinations, MRIs, and biopsies when necessary, and to initiate treatment when needed. In patients requiring surgery or radiotherapy, the choice is made by considering cancer control along with urinary and sexual function. The PACE-B study showed that five sessions of stereotactic radiotherapy can be an effective alternative to longer programs in selected low and moderate-risk patients. [1,2]
In metastatic, hormone-sensitive disease, the addition of next-generation hormone drugs has become an important approach in patients suitable for testosterone-suppressing therapy. In some patients, docetaxel is also included in the plan. The 2025 US approval of darolutamide for use with primary hormone suppression therapy and without mandatory docetaxel is one of the developments that expands the options. Which combination is appropriate is determined according to the extent of the spread and the patient's overall health. [1,3]
Genetic investigations also guide treatment earlier. Alterations in BRCA1/2 and other DNA repair genes help identify patients who may benefit from PARP inhibitors. In 2026, the use of talazoparibin in combination with enzalutamide was approved in the US for metastatic hormone-sensitive disease carrying specific DNA repair gene alterations. This approach also maintains basic testosterone suppression therapy; the presence of genetic findings does not mean that all patients will benefit equally. [4]
Another development in 2026 was the approval in the US of capivasertibin in combination with abirateron and prednisone in metastatic hormone-sensitive patients with detected PTEN deficiency. This treatment targets one of the cell's growth signals in addition to hormone suppression. PTEN assessment should be done with the appropriate test; side effects such as elevated blood sugar, diarrhea, and skin reactions should be monitored. This is an option for a specific group, not for every metastatic patient. [5]
PSMA-targeted radioligand therapies are also advancing to earlier stages. Lutetium-177 is applied by binding to a molecule that delivers radiation to cancer cells carrying PSMA. In 2026, the use of lutetium-177 vipivotide tetraxethane in combination with next-generation hormone therapy in metastatic hormone-sensitive patients with suitable PSMA PET results was approved in the US; basic hormone suppression also continues. Kidney function and blood values are evaluated before treatment, and regular follow-up is performed during application. [6]
The value of new options becomes apparent when used in a way that suits the patient's needs. Bone health, mobility, cardiovascular health, and quality of life should be considered throughout the treatment. The expected benefits, side effects, and accessibility in Türkiye should be openly discussed with the patient and their family before a decision is made.
Sources [1] NCI · Prostate cancer | [2] PACE-B · NEJM | [3] ARANOTE · FDA | [4] TALAPRO-3 · FDA 2026 | [5] CAPItello-281 · FDA 2026 | [6] PSMAddition · FDA 2026
